ALL, Adult

14 clinical trials · Condition

Record	Firm	Date
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL (NCT04722848)	Gruppo Italiano Malattie EMatologiche dell'Adulto	2021-09-08
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL (NCT05026229)	First Affiliated Hospital Xi'an Jiaotong University	2021-09-06
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL (NCT05024357)	First Affiliated Hospital Xi'an Jiaotong University	2021-09-06
Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS (NCT04482894)	University of Virginia	2020-08-19
COVID-19 Survey Study on Dietary Intake, Physical Activity and Overall Well-being (NCT04357041)	Clinical Nutrition Research Center, Illinois Institute of Technology	2020-04-17
Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL (NCT03751709)	Cedars-Sinai Medical Center	2020-02-14
A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS (NCT03884829)	Cyclacel Pharmaceuticals, Inc.	2019-03-25
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. (NCT03541083)	Stichting Hemato-Oncologie voor Volwassenen Nederland	2018-06-04

Every clearance here is in the API, with alerts when new ones post.